Protalix BioTherapeutics Inc (PLX)

Add to Watchlists
Create an Alert
0.4101 -0.05  -10.65% NYSE AM Mar 25, 20:00 Real time USD
View Full Chart
PLX Price Chart
View All Events

PLX Events

Date Type Description
05/09/2019 08:30 EDT Misc Protalix BioTherapeutics Inc First Quarter Earnings Conference Call in 2019
05/09/2019 Earnings Protalix BioTherapeutics Inc First Quarter Earnings in 2019 Release
03/14/2019 08:30 EDT Misc Protalix BioTherapeutics Inc Fourth Quarter Earnings Conference Call in 2018
03/14/2019 Earnings Protalix BioTherapeutics Inc Fourth Quarter Earnings in 2018 Release
11/07/2018 08:30 EST Misc Protalix BioTherapeutics Inc Third Quarter Earnings Conference Call in 2018
11/07/2018 Earnings Protalix BioTherapeutics Inc Third Quarter Earnings in 2018 Release
08/09/2018 08:30 EDT Misc Protalix BioTherapeutics Inc Second Quarter Earnings Conference Call in 2018
08/09/2018 Earnings Protalix BioTherapeutics Inc Second Quarter Earnings Results in 2018
05/13/2018 13:00 IST Misc Protalix BioTherapeutics Inc Annual General Meeting in 2017
05/09/2018 08:30 EDT Misc Protalix BioTherapeutics Inc First Quarter Earnings Conference Call in 2018
View All Performance Charts

PLX Total Returns Comparison

Advertisement

PLX One Page Reports

Edit

Profile

  • URL: http://www.protalix.com
  • Investor Relations URL: http://phx.corporate-ir.net/phoenix.zhtml?c=101161&p=irol-IRHome
  • HQ State/Province: N/A
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Blend
  • Next Earnings Release: May. 09, 2019
  • Last Earnings Release: Mar. 14, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa, for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. Its pipeline products include Alidornase Alfa, Pegunigalsidase Alfa, and Oprx-106. The company's primary sources of revenues include its sales of taliglucerase alfa in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.

PLX Comparables

Edit

PLX Excel Add-In Codes

  • Name: =YCI("PLX","name")
  • Description: =YCI("PLX","description")
  • Sector: =YCI("PLX","sector")
  • Industry: =YCI("PLX","industry")
  • Est. Current Fiscal Year End: =YCI("PLX","fye")

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.